

|   |  |  |  |
|---|--|--|--|
| 1. DATE ISSUED MM/DD/YYYY<br>07/15/2020   |  | 1a. SUPERSEDES AWARD NOTICE dated<br>except that any additions or restrictions previously imposed remain in effect unless specifically rescinded |  |
| 2. CFDA NO.<br>93.323 - Epidemiology and Laboratory Capacity for Infectious Diseases (ELC)  |  |  |  |
| 3. ASSISTANCE TYPE Cooperative Agreement  |  |  |  |
| 4. GRANT NO. 5 NU50CK000546-02-00<br>Formerly   |  | 5. TYPE OF AWARD<br>Demonstration  |  |
| 4a. FAIN NU50CK000546   |  | 5a. ACTION TYPE Non-Competing Continuation   |  |
| 6. PROJECT PERIOD MM/DD/YYYY<br>From 08/01/2019   |  | Through 07/31/2024   |  |
| 7. BUDGET PERIOD MM/DD/YYYY<br>From 08/01/2020  |  | Through 07/31/2021   |  |
| 8. TITLE OF PROJECT (OR PROGRAM)<br>CK19-1904 Epidemiology and Laboratory Capacity for Prevention and Control of Emerging Infectious Diseases (ELC) |  |  |  |

**DEPARTMENT OF HEALTH AND HUMAN SERVICES  
Centers for Disease Control and Prevention**

2939 Brandywine Road  
Atlanta, GA 30341

**NOTICE OF AWARD**  
AUTHORIZATION (Legislation/Regulations)  
301(A)AND317(K)(2)PHS42USC241(A)247B(K)2

|  |  |
|--|--|
| 9a. GRANTEE NAME AND ADDRESS<br>HEALTH AND SENIOR SERVICES, MISSOURI DEPARTMENT OF<br>920 Wildwood Dr<br>Jefferson City, MO 65109-5796 | 9b. GRANTEE PROJECT DIRECTOR<br>HOWARD PUE<br>920 WILDWOOD DRIVE P.O. BOX 570<br>MISSOURI STATE DEPT. OF HEALTH &<br>JEFFERSON CITY, MO 65102-0570<br>Phone: [NO DATA] |
| 10a. GRANTEE AUTHORIZING OFFICIAL<br>Ms. Tonya R Loucks<br>920 Wildwood Drive<br>Jefferson City, MO 65109-5796<br>Phone: 573-751-6014  | 10b. FEDERAL PROJECT OFFICER<br>Angelica O'Connor<br>1600 Clifton Rd<br>Atlanta, GA 30333<br>Phone: 404-639-7379   |

**ALL AMOUNTS ARE SHOWN IN USD**

|   |  |   |                    |
|---|--|---|--------------------|
| 11. APPROVED BUDGET (Excludes Direct Assistance)  |  | 12. AWARD COMPUTATION   |                    |
| I Financial Assistance from the Federal Awarding Agency Only  |  | a. Amount of Federal Financial Assistance (from item 11m) 2,298,741.00  |                    |
| II Total project costs including grant funds and all other financial participation <input type="checkbox"/> |  | b. Less Unobligated Balance From Prior Budget Periods 0.00  |                    |
| a. Salaries and WageS ..... 778,594.00  |  | c. Less Cumulative Prior Award(s) This Budget Period 0.00   |                    |
| b. Fringe Benefits ..... 437,492.00   |  | d. AMOUNT OF FINANCIAL ASSISTANCE THIS ACTION 2,298,741.00  |                    |
| c. Total Personnel Costs ..... 1,216,086.00   |  | 13. Total Federal Funds Awarded to Date for Project Period 151,474,819.00   |                    |
| d. Equipment ..... 0.00   |  | 14. RECOMMENDED FUTURE SUPPORT  |                    |
| e. Supplies ..... 182,788.00  |  | (Subject to the availability of funds and satisfactory progress of the project):  |                    |
| f. Travel ..... 24,184.00   |  | YEAR  | TOTAL DIRECT COSTS |
| g. Construction ..... 0.00  |  | a. 3  | d. 6               |
| h. Other ..... 355,407.00   |  | b. 4  | e. 7               |
| i. Contractual ..... 271,736.00   |  | c. 5  | f. 8               |
| j. TOTAL DIRECT COSTS → 2,050,201.00  |  | 15. PROGRAM INCOME SHALL BE USED IN ACCORD WITH ONE OF THE FOLLOWING ALTERNATIVES:  |                    |
| k. INDIRECT COSTS 248,540.00  |  | a. DEDUCTION  |                    |
| l. TOTAL APPROVED BUDGET 2,298,741.00   |  | b. ADDITIONAL COSTS   |                    |
| m. Federal Share 2,298,741.00   |  | c. MATCHING   |                    |
| n. Non-Federal Share 0.00   |  | d. OTHER RESEARCH (Add / Deduct Option)   |                    |
|   |  | e. OTHER (See REMARKS)  |                    |
|   |  | 16. THIS AWARD IS BASED ON AN APPLICATION SUBMITTED TO, AND AS APPROVED BY, THE FEDERAL AWARDDING AGENCY ON THE ABOVE TITLED PROJECT AND IS SUBJECT TO THE TERMS AND CONDITIONS INCORPORATED EITHER DIRECTLY OR BY REFERENCE IN THE FOLLOWING:  |                    |
|   |  | a. The grant program legislation  |                    |
|   |  | b. The grant program regulations.   |                    |
|   |  | c. This award notice including terms and conditions, if any, noted below under REMARKS.   |                    |
|   |  | d. Federal administrative requirements, cost principles and audit requirements applicable to this grant.  |                    |
|   |  | In the event there are conflicting or otherwise inconsistent policies applicable to the grant, the above order of precedence shall prevail. Acceptance of the grant terms and conditions is acknowledged by the grantee when funds are drawn or otherwise obtained from the grant payment system. |                    |

REMARKS (Other Terms and Conditions Attached -  Yes  No)

**GRANTS MANAGEMENT OFFICIAL:**

Kathy Raible  
2920 Brandywine Rd  
Mailstop E09  
Atlanta, GA 30341-5539  
Phone: 770-488-2045

|                    |                   |                     |                     |                    |
|--------------------|-------------------|---------------------|---------------------|--------------------|
| 17.OBJ CLASS 41.51 | 18a. VENDOR CODE  | 18b. EIN            | 19. DUNS 878092600  | 20. CONG. DIST. 03 |
| FY-ACCOUNT NO.     | DOCUMENT NO.      | ADMINISTRATIVE CODE | AMT ACTION FIN ASST | APPROPRIATION      |
| 21. a. 0-9390EPX   | b. 19NU50CK000546 | c. CK               | d. \$0.00           | e. 75-2022-0943    |
| 22. a. 0-9211175   | b. 19NU50CK000546 | c. CK               | d. \$166,070.00     | e. 75-20-0949      |
| 23. a. 0-939014P   | b. 19NU50CK000546 | c. CK               | d. \$73,965.00      | e. 75-20-0949      |

NOTICE OF AWARD (Continuation Sheet)

|                                |                           |
|--------------------------------|---------------------------|
| PAGE 2 of 3                    | DATE ISSUED<br>07/15/2020 |
| GRANT NO. 5 NU50CK000546-02-00 |                           |

| FY-ACCOUNT NO.  | DOCUMENT NO.        | ADMINISTRATIVE CODE | AMT ACTION FIN ASST | APPROPRIATION   |
|-----------------|---------------------|---------------------|---------------------|-----------------|
| 24.a. 0-93901FT | b. 19NU50CK000546   | c. CK               | d. \$287,992.00     | e. 75-20-0959   |
| 25.a. 0-93905VH | b. 19NU50CK000546   | c. CK               | d. \$149,740.00     | e. 75-20-0949   |
| 26.a. 0-93906EZ | b. 19NU50CK000546   | c. CK               | d. \$29,129.00      | e. 75-20-0947   |
| 27.a. 0-93906N9 | b. 19NU50CK000546   | c. CK               | d. \$14,932.00      | e. 75-20-0949   |
| 28.a. 0-93908MV | b. 19NU50CK000546   | c. CK               | d. \$302,115.00     | e. 75-20-0949   |
| 29.a. 0-93909QZ | b. 19NU50CK000546   | c. CK               | d. \$112,552.00     | e. 75-X-0951    |
| 30.a. 0-93909S9 | b. 19NU50CK000546   | c. CK               | d. \$1,117.00       | e. 75-20-0949   |
| 31.a. 0-93909UW | b. 19NU50CK000546   | c. CK               | d. \$320,927.00     | e. 75-X-0949    |
| 32.a. 0-9390EUT | b. 19NU50CK000546   | c. CK               | d. \$248,098.00     | e. 75-20-0959   |
| 33.a. 0-9390EWQ | b. 19NU50CK000546C3 | c. CK               | d. \$292,481.00     | e. 75-2024-0943 |
| 34.a. 0-939ZSCE | b. 19NU50CK000546   | c. CK               | d. \$109,734.00     | e. 75-20-0951   |
| 35.a. 0-939ZVJC | b. 19NU50CK000546   | c. CK               | d. \$189,889.00     | e. 75-20-0949   |

Direct Assistance

| BUDGET CATEGORIES | PREVIOUS AMOUNT (A) | AMOUNT THIS ACTION (B) | TOTAL (A + B) |
|-------------------|---------------------|------------------------|---------------|
| Personnel         | \$0.00              | \$0.00                 | \$0.00        |
| Fringe Benefits   | \$0.00              | \$0.00                 | \$0.00        |
| Travel            | \$0.00              | \$0.00                 | \$0.00        |
| Equipment         | \$0.00              | \$0.00                 | \$0.00        |
| Supplies          | \$0.00              | \$0.00                 | \$0.00        |
| Contractual       | \$0.00              | \$0.00                 | \$0.00        |
| Construction      | \$0.00              | \$0.00                 | \$0.00        |
| Other             | \$0.00              | \$0.00                 | \$0.00        |
| Total             | \$0.00              | \$0.00                 | \$0.00        |

NOTICE OF AWARD (Continuation Sheet)

|                                |                           |
|--------------------------------|---------------------------|
| PAGE 3 of 3                    | DATE ISSUED<br>07/15/2020 |
| GRANT NO. 5 NU50CK000546-02-00 |                           |

---

| Federal Financial Report Cycle |                           |                |                           |
|--------------------------------|---------------------------|----------------|---------------------------|
| Reporting Period Start Date    | Reporting Period End Date | Reporting Type | Reporting Period Due Date |
| 08/01/2019                     | 07/31/2020                | Annual         | 10/29/2020                |

# AWARD ATTACHMENTS

Missouri Department of Health

5 NU50CK000546-02-00

---

1. Notice of Cooperative Agreement

## AWARD INFORMATION

**Incorporation:** In addition to the federal laws, regulations, policies, and CDC General Terms and Conditions for Non-research awards at <https://www.cdc.gov/grants/federalregulationspolicies/index.html>, the Centers for Disease Control and Prevention (CDC) hereby incorporates Notice of Funding Opportunity (NOFO) number CDC-RFA-CK19-1904, entitled “Epidemiology and Laboratory Capacity for Prevention and Control of Emerging Infectious Diseases (ELC),” and application dated May 1, 2020, as may be amended, which are hereby made a part of this Non-research award, hereinafter referred to as the Notice of Award (NoA).

**Approved Funding:** Funding in the amount of **\$2,298,741** is approved for the **Year 02** budget period, which is **August 1, 2020** through **July 31, 2021**. All future year funding will be based on satisfactory programmatic progress and the availability of funds.

The federal award amount is subject to adjustment based on total allowable costs incurred and/or the value of any third party in-kind contribution when applicable.

Note: Refer to the Payment Information section for Payment Management System (PMS) subaccount information.

The NOFO provides for the funding of multiple components under this award. The approved component funding levels for this notice of award are:

| <b>NOFO Component</b>  | <b>Amount</b> |
|--|---------------|
| <b>Core Funding</b>  | \$2,006,260   |
| <b>COVID-19 Project W (Infants w/Congenital Defects SET-NET)</b> | \$192,481     |
| <b>COVID-19 Project O (VPD MIS-C)</b>                            | \$100,000     |
| <b>Disaster Relief Cross-cutting Epi &amp; Lab Program (A2)</b>  | \$0           |
| <b>Disaster Relief Vector-borne (H) Program</b>                  | \$0           |

**Recipients have until May 31, 2022 to expend all COVID-19 funds awarded herein.**

**Overtime:** Because overtime costs are a very likely and reasonable expense during the response to COVID-19, CDC will allow recipients to include projected overtime in their budgets. Recipients should be careful to estimate costs based on current real-time needs and will still be required to follow federal rules and regulations in accounting for the employees’ time and effort.

**Coronavirus Disease 2019 (COVID-19) Funds:** A recipient of a grant or cooperative agreement awarded by the Department of Health and Human Services (HHS) with funds made available under the Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020 (P.L. 116-123); the Coronavirus Aid, Relief, and Economic Security Act, 2020 (the “CARES Act”) (P.L. 116-136); and/or the Paycheck Protection Program and Health Care Enhancement Act (P.L. 116-139) agrees, as applicable to the award, to: 1) comply with existing and/or future directives and guidance from the Secretary regarding control of the spread of COVID-19; 2) in consultation and coordination with HHS, provide, commensurate with the condition of the individual, COVID-19 patient care regardless of the individual’s home jurisdiction and/or appropriate public health measures (e.g., social distancing, home isolation);

and 3) assist the United States Government in the implementation and enforcement of federal orders related to quarantine and isolation.

In addition, to the extent applicable, Recipient will comply with Section 18115 of the CARES Act, with respect to the reporting to the HHS Secretary of results of tests intended to detect SARS-CoV-2 or to diagnose a possible case of COVID-19. Such reporting shall be in accordance with guidance and direction from HHS and/or CDC. HHS laboratory reporting guidance is posted at: <https://www.hhs.gov/sites/default/files/covid-19-laboratory-data-reporting-guidance.pdf>.

Further, consistent with the full scope of applicable grant regulations (45 C.F.R. 75.322), the purpose of this award, and the underlying funding, the recipient is expected to provide to CDC copies of and/or access to COVID-19 data collected with these funds, including but not limited to data related to COVID-19 testing. CDC will specify in further guidance and directives what is encompassed by this requirement.

This award is contingent upon agreement by the recipient to comply with existing and future guidance from the HHS Secretary regarding control of the spread of COVID-19. In addition, recipient is expected to flow down these terms to any subaward, to the extent applicable to activities set out in such subaward.

#### **Unallowable Costs:**

- Research
- Clinical care
- Publicity and propaganda (lobbying):
  - Other than for normal and recognized executive-legislative relationships, no funds may be used for:
    - publicity or propaganda purposes, for the preparation, distribution, or use of any material designed to support or defeat the enactment of legislation before any legislative body
    - the salary or expenses of any grant or contract recipient, or agent acting for such recipient, related to any activity designed to influence the enactment of legislation, appropriations, regulation, administrative action, or Executive order proposed or pending before any legislative body
  - See Additional Requirement (AR) 12 for detailed guidance on this prohibition and additional guidance on lobbying for CDC recipients:  
[https://www.cdc.gov/grants/documents/Anti-Lobbying\\_Restrictions\\_for\\_CDC\\_Grantees\\_July\\_2012.pdf](https://www.cdc.gov/grants/documents/Anti-Lobbying_Restrictions_for_CDC_Grantees_July_2012.pdf)
- All unallowable costs cited in CDC-RFA-CK19-1904 remain in effect, unless specifically amended in this guidance, in accordance with 45 CFR Part 75 – Uniform Administrative Requirements, Cost Principles, And Audit Requirements for HHS Awards.

Funding in the amount of **\$2,298,741** is approved for budget period **August 1, 2020** through **July 31, 2021**. The recipient must obligate, expend and disburse all funds by **July 31, 2022**. After the budget period has expired, CDC may de-obligate all funds not expended and disbursed, including unliquidated obligations.

Note: Refer to the Payment Information section for draw down and Payment Management

System (PMS) subaccount information.

**Financial Assistance Mechanism:** Cooperative Agreement

**Substantial Involvement by CDC:** This is a cooperative agreement and CDC will have substantial programmatic involvement after the award is made. Substantial involvement is in addition to all post-award monitoring, technical assistance, and performance reviews undertaken in the normal course of stewardship of federal funds.

CDC program staff will assist, coordinate, or participate in carrying out effort under the award, and recipients agree to the responsibilities therein, as detailed in the NOFO.

- Technical assistance in the following: evaluation, performance measurement, work plan development, program planning, and specific subject matter expertise for ELC Program or Projects.
- National coordination of activities where appropriate.
- Targeted Electronic Data Exchange (EDX) technical assistance to public health departments and public health labs.

**Budget Revision Requirement:** By September 1, 2020 the recipient must submit a revised budget with a narrative justification. Failure to submit the required information in a timely manner may adversely affect the future funding of this project. If the information cannot be provided by the due date, you are required to contact the GMS/GMO identified in the CDC Staff Contacts section of this notice before the due date.

**COVID-19 Expansion Revised Budget Requirements** - A separate narrative and workplan must be submitted in accordance with the attached COVID-19 guidance and must also be uploaded in GMM as an amendment with a SF424A.

**Expanded Authority:** The recipient is permitted the following expanded authority in the administration of the award.

- Carryover of unobligated balances from one budget period to a subsequent budget period. Unobligated funds may be used for purposes within the scope of the project as originally approved. Recipients will report use, or intended use, of unobligated funds in Section 12 "Remarks" of the annual Federal Financial Report. If the GMO determines that some or all of the unobligated funds are not necessary to complete the project, the GMO may restrict the recipient's authority to automatically carry over unobligated balances in the future, use the balance to reduce or offset CDC funding for a subsequent budget period, or use a combination of these actions.

**Program Income:** Any program income generated under this grant or cooperative agreement will be used in accordance with the Addition alternative.

**Addition alternative:** Under this alternative, program income is added to the funds committed to the project/program and is used to further eligible project/program objectives.

#### **FUNDING RESTRICTIONS AND LIMITATIONS**

**Indirect Costs:** Indirect costs are approved based on the negotiated indirect cost rate

agreement dated March 17, 2020 that calculates a fixed rate at 21.10% of the base, including direct salaries and wages with all fringe benefits. The effective dates of this indirect cost rate are from July 1, 2020 to June 30, 2021.

## REPORTING REQUIREMENTS

### **COVID-19 - Additional Reporting Requirements:**

- Monthly fiscal reports (beginning 60 days after NOAs are issued)
- Quarterly progress reports on status of timelines, goals, and objectives as defined by CDC in approved work plans
- Quarterly Performance measure data
- CDC may require recipients to develop annual progress reports (APRs). CDC will provide APR guidance and optional templates should they be required

**Performance Progress and Monitoring:** Performance information collection initiated under this grant/cooperative agreement has been approved by the Office of Management and Budget under **OMB Number 0920-1132, “Performance Progress and Monitoring Report”, Expiration Date 10/31/2022.** The components of the PPMR are available for download at: <https://www.cdc.gov/grants/alreadyhavegrant/Reporting.html> .

**Required Disclosures for Federal Awardee Performance and Integrity Information System (FAPIIS):** Consistent with 45 CFR 75.113, applicants and recipients must disclose in a timely manner, in writing to the CDC, with a copy to the HHS Office of Inspector General (OIG), all information related to violations of federal criminal law involving fraud, bribery, or gratuity violations potentially affecting the federal award. Subrecipients must disclose, in a timely manner in writing to the prime recipient (pass through entity) and the HHS OIG, all information related to violations of federal criminal law involving fraud, bribery, or gratuity violations potentially affecting the federal award. Disclosures must be sent in writing to the CDC and to the HHS OIG at the following addresses:

CDC, Office of Grants Services  
Tonya M. Jenkins, Grants Management Specialist (Contractor)  
Time Solutions  
Centers for Disease Control and Prevention  
Branch 1  
2939 Flowers Road, MS-TV-2  
Atlanta, GA 30341  
Email: PJO6@CDC.GOV (Include “Mandatory Grant Disclosures” in subject line)

AND

U.S. Department of Health and Human Services  
Office of the Inspector General  
ATTN: Mandatory Grant Disclosures, Intake Coordinator  
330 Independence Avenue, SW  
Cohen Building, Room 5527  
Washington, DC 20201

Fax: (202)-205-0604 (Include “Mandatory Grant Disclosures” in subject line) or  
Email: [MandatoryGranteeDisclosures@oig.hhs.gov](mailto:MandatoryGranteeDisclosures@oig.hhs.gov)



Recipients must include this mandatory disclosure requirement in all subawards and contracts under this award.

Failure to make required disclosures can result in any of the remedies described in 45 CFR 75.371. Remedies for noncompliance, including suspension or debarment (See 2 CFR parts 180 and 376, and 31 U.S.C. 3321).

CDC is required to report any termination of a federal award prior to the end of the period of performance due to material failure to comply with the terms and conditions of this award in the OMB-designated integrity and performance system accessible through SAM (currently FAPIIS). (45 CFR 75.372(b)) CDC must also notify the recipient if the federal award is terminated for failure to comply with the federal statutes, regulations, or terms and conditions of the federal award. (45 CFR 75.373(b))

#### **PAYMENT INFORMATION**

*The HHS Office of the Inspector General (OIG) maintains a toll-free number (1-800-HHS-TIPS [1-800-447-8477]) for receiving information concerning fraud, waste, or abuse under grants and cooperative agreements. Information also may be submitted by e-mail to [hhstips@oig.hhs.gov](mailto:hhstips@oig.hhs.gov) or by mail to Office of the Inspector General, Department of Health and Human Services, Attn: HOTLINE, 330 Independence Ave., SW, Washington DC 20201. Such reports are treated as sensitive material and submitters may decline to give their names if they choose to remain anonymous.*

**Payment Management System Subaccount:** Funds awarded in support of approved activities have been obligated in a subaccount in the PMS, herein identified as the “P Account”. Funds must be used in support of approved activities in the NOFO and the approved application.

The grant document number identified on the bottom of Page 1 of the Notice of Award must be known in order to draw down funds.

|                        |
|------------------------|
| <b>Component:</b> Core |
|------------------------|

|  |
|--|
| <b>Document Number:</b> 19NU50CK000546 |
|--|

|                            |
|----------------------------|
| <b>Component:</b> COVID-19 |
|----------------------------|

|  |
|--|
| <b>Document Number:</b> 19NU50CK000546C3 |
|--|

#### **CDC Staff Contacts**

**Grants Management Specialist:** The GMS is the federal staff member responsible for the day-to-day management of grants and cooperative agreements. The GMS is the primary contact of recipients for business and administrative matters pertinent to grant awards.

**GMS Contact:**

Tonya M. Jenkins, Grants Management Specialist (Contractor)  
Time Solutions  
Centers for Disease Control and Prevention  
Branch 1  
2939 Flowers Road, MS-TV-2  
Atlanta, GA 30341

Telephone: 404-498-2399  
Email: PJO6@CDC.GOV

**Program/Project Officer:** The PO is the federal official responsible for monitoring the programmatic, scientific, and/or technical aspects of grants and cooperative agreements, as well as contributing to the effort of the award under cooperative agreements.

**Grants Management Officer:** The GMO is the federal official responsible for the business and other non-programmatic aspects of grant awards. The GMO is the only official authorized to obligate federal funds and is responsible for signing the NoA, including revisions to the NoA that change the terms and conditions. The GMO serves as the counterpart to the business officer of the recipient organization.